Fed. Circ. Revives Galderma's Patents On Rosacea Drug

By Alex Lawson (August 7, 2013, 5:48 PM EDT) -- The Federal Circuit on Wednesday vacated a district court's finding that two patents held by Galderma Laboratories Inc. for rosacea drug Oracea were invalid, ruling that the district judge did not adequately examine certain claims in light of prior art presented by generics manufacturer Mylan Pharmaceuticals Inc....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!